# Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)

> **NCT07714616** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 1600 (estimated)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg

## Key facts

- **NCT ID:** NCT07714616
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-05-31
- **Primary completion:** 2029-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 1600 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714616, "Evaluation of the Contraceptive Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-Dose Estrogen (LUNA)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07714616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*